Volume 35, Issue 3 (6-2024)
Studies in Medical Sciences 2024, 35(3): 174-181 |
Back to browse issues page
Ethics code: IR.QUMS.REC.1402.209
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Jamalzadeh A, Khakpour M, Fardsanei F, Nikkhahi F. EFFICACY OF FOSFOMYCIN AGAINST MULTIDRUG-RESISTANT ESCHERICHIA COLI ISOLATED FROM CULTURES OF PATIENTS WITH URINARY TRACT INFECTIONS. Studies in Medical Sciences 2024; 35 (3) :174-181
URL: http://umj.umsu.ac.ir/article-1-6215-en.html
URL: http://umj.umsu.ac.ir/article-1-6215-en.html
Assistant Professor of Medical Bacteriology, Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran (Corresponding Author) , atefeh_fardsanei@yahoo.com
Abstract: (1308 Views)
Background & Aims: Escherichia coli, a gram-negative bacillus, is one of the most common pathogens causing urinary tract infections. Several studies have demonstrated that the antibiotic fosfomycin has a significant inhibitory effect on Gram-negative pathogens, including Escherichia coli, by inhibiting peptidoglycan production. This study aimed to better understand the effect of fosfomycin against multidrug-resistant Escherichia coli causing urinary tract infections.
Materials and Methods: In this epidemiologic-descriptive study, 90 Escherichia coli isolates were collected between October 1401 and October 1402 from urine samples of teaching hospitals in Qazvin city. ESBL- and AmpC-producing strains were identified using the phenotypic method. Data were evaluated and analyzed using SPSS software version 2022 with a significance level of less than 0.05.
Results: Among the 90 isolates of Escherichia coli, the highest antibiotic resistance was observed for ampicillin (96.6%), cefotaxime (90%), and ceftazidime (84.4%), while the highest susceptibility was related to the antibiotics fosfomycin (98.9%), meropenem (98.8%), gentamicin (88.8%), and nitrofurantoin (84.4%).
Conclusion: With the increase in antibiotic resistance and the spread of strains producing beta-lactamase enzymes, the treatment of infections caused by these strains has become a serious problem. In this study, the susceptibility of Escherichia coli isolates that produce broad-spectrum beta-lactamases and are resistant to multiple drugs to fosfomycin was investigated. It was found that 89 (98.9%) isolates were sensitive to fosfomycin, indicating that fosfomycin is an effective antibiotic against ESBL isolates in Iran.
Materials and Methods: In this epidemiologic-descriptive study, 90 Escherichia coli isolates were collected between October 1401 and October 1402 from urine samples of teaching hospitals in Qazvin city. ESBL- and AmpC-producing strains were identified using the phenotypic method. Data were evaluated and analyzed using SPSS software version 2022 with a significance level of less than 0.05.
Results: Among the 90 isolates of Escherichia coli, the highest antibiotic resistance was observed for ampicillin (96.6%), cefotaxime (90%), and ceftazidime (84.4%), while the highest susceptibility was related to the antibiotics fosfomycin (98.9%), meropenem (98.8%), gentamicin (88.8%), and nitrofurantoin (84.4%).
Conclusion: With the increase in antibiotic resistance and the spread of strains producing beta-lactamase enzymes, the treatment of infections caused by these strains has become a serious problem. In this study, the susceptibility of Escherichia coli isolates that produce broad-spectrum beta-lactamases and are resistant to multiple drugs to fosfomycin was investigated. It was found that 89 (98.9%) isolates were sensitive to fosfomycin, indicating that fosfomycin is an effective antibiotic against ESBL isolates in Iran.
Type of Study: Research |
Subject:
میکروبیولوژی
References
1. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 2012 Jul;25(3):450-70. [DOI:10.1128/CMR.05041-11] [PMID]
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad Bugs, No Drugs: No ESKAPE An Update from the Infectious Diseases Society of America. Clin Infect Dis 2009 Jan;48(1):1-12. [DOI:10.1086/595011] [PMID]
3. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary Tract Infection. Ann Epidemiol 2000 Nov;10(8):509-15. [DOI:10.1016/S1047-2797(00)00072-7] [PMID]
4. Wilson ML, Gaido L. Laboratory Diagnosis of Urinary Tract Infections in Adult Patients. Clin Infect Dis 2004 Apr 15;38(8):1150-8. [DOI:10.1086/383029] [PMID]
5. Dash M, Padhi S, Mohanty I, Panda P, Parida B. Antimicrobial resistance in pathogens causing urinary tract infections in a rural community of Odisha, India. J Fam Community Med 2013;20(1):20. [DOI:10.4103/2230-8229.108180] [PMID]
6. Darabi N, Yousefi S, Hosseini Jazani N. DETERMINATION OF THE EFFICACY OF PHOSPHOMYCIN ON IMIPENEM RESISTANT KLEBSIELLA PNEUMONIAE CLINICAL ISOLATES. URMIAMJ 2016 Feb 1;26(11):960-8. [google scholar]
7. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev 2016 Apr;29(2):321-47. [DOI:10.1128/CMR.00068-15] [PMID]
8. Dijkmans AC, Ortiz Zacarías NV, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics 2017 Oct 31;6(4):24. [DOI:10.3390/antibiotics6040024] [PMID]
9. Ong A, Mahobia N, Browning D, Schembri M, Somani BK. Trends in antibiotic resistance for over 700,000 Escherichia coli positive urinary tract infections over six years (2014-2019) from a university teaching hospital. Cent Eur J Urol 2021;74(2):249-54. [DOI:10.5173/ceju.2021.0053]
10. Tutone M, Bjerklund Johansen TE, Cai T, Mushtaq S, Livermore DM. SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study. Int J Antimicrob Agents 2022 May 1;59(5):106574. [DOI:10.1016/j.ijantimicag.2022.106574] [PMID]
11. Baran C, Küçükcan A. Antimicrobial susceptibility of bacteria isolated from urine cultures in Southern Turkey. Curr Urol 2022 Sep;16(3):180. [DOI:10.1097/CU9.0000000000000144] [PMID]
12. Yeganeh-Sefidan F, Ghotaslou R, Akhi MT, Sadeghi MR, Mohammadzadeh-Asl Y, Baghi HB. Fosfomycin, interesting alternative drug for treatment of urinary tract infections created by multiple drug resistant and extended spectrum β-lactamase producing strains. Iran J Microbiol 2016 May 14;8(2):125-31. [PMID] [PMCID]
13. Ghanavati R, Ohadi E, Kazemian H, Yazdani F, Torki A, Kalani BS, et al. Evaluation of Fosfomycin Activity Against Extended Spectrum Beta Lactamase (ESBL) Producing Enterobacteriaceae Isolated from Three Centers of Tehran, Iran. Recent Patents Anti-Infect Drug Disc 2018;13(2):180-6. [DOI:10.2174/1574891X13666180517075803] [PMID]
14. Marino A, Stracquadanio S, Bellanca CM, Augello E, Ceccarelli M, Cantarella G, et al. Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations. Infect Dis Rep 2022 Aug;14(4):621-34. [DOI:10.3390/idr14040067] [PMID]
15. Novelli A, Rosi E. Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections. J Chemother 2017 Dec 22;29(sup1):10-8. [DOI:10.1080/1120009X.2017.1380357] [PMID]
16. World Health Organization. (2022). Antimicrobial Resistance. Retrieved from https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance [URL]
17. Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009 Oct;30(10):972-6. [DOI:10.1086/605922] [PMID]
18. Livermore DM. Current Epidemiology and Growing Resistance of Gram-Negative Pathogens. Korean J Intern Med 2012 Jun;27(2):128-42. [DOI:10.3904/kjim.2012.27.2.128] [PMID]
19. Tzouvelekis LS, Tzelepi E, Tassios PT, Legakis NJ. CTX-M-type beta-lactamases: an emerging group of extended-spectrum enzymes. Int J Antimicrob Agents 2000 Mar;14(2):137-42. [DOI:10.1016/S0924-8579(99)00165-X] [PMID]
20. Abdelraheem WM, Mahdi WKM, Abuelela IS, Hassuna NA. High incidence of fosfomycin-resistant uropathogenic E. coli among children. BMC Infect Dis 2023 Jul 17;23(1):475. [DOI:10.1186/s12879-023-08449-9] [PMID]
21. Ríos E, Del Carmen López Diaz M, Culebras E, Rodríguez-Avial I, Rodríguez-Avial C. Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum β-lactamase-production in urinary isolates of Escherichia coli. Med Microbiol Immunol (Berl) 2022 Dec;211(5-6):269-72. [DOI:10.1007/s00430-022-00749-2] [PMID]
22. Parajuli NP, Maharjan P, Parajuli H, Joshi G, Paudel D, Sayami S, et al. High rates of multidrug resistance among uropathogenic Escherichia coli in children and analyses of ESBL producers from Nepal. Antimicrob Resist Infect Control 2017;6:9. [DOI:10.1186/s13756-016-0168-6] [PMID]
23. Dehbanipour R, Rastaghi S, Sedighi M, Maleki N, Faghri J. High prevalence of multidrug-resistance uropathogenic Escherichia coli strains, Isfahan, Iran. J Nat Sci Biol Med 2016;7(1):22-6. [DOI:10.4103/0976-9668.175020] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
